We evaluated temporal trends in systemic therapy use in patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma. We used data from a large national cancer registry and assessed characteristics associated with the receipt of systemic treatment.Materials and Methods:
We reviewed the NCDB to identify patients with stage IV renal cell carcinoma who underwent cytoreductive nephrectomy between 1998 and 2010. Systemic therapy was defined as immunotherapy and/or chemotherapy, including targeted agents. We evaluated associations between clinicopathological features and receipt of systemic therapy using multivariable logistic regression with generalized estimating equations.Results:
Of 22,409 patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy 8,830 (39%) received systemic therapy. Use of systemic therapy increased from 32% of cases in 1998 to 49% in 2010 (p <0.001). After adjustment older patient age (71 years or greater OR 0.36, CI 0.31–0.43), increasing comorbidity count (Charlson comorbidity index 2 or greater OR 0.79, 95% CI 0.68–0.92), papillary histology (OR 0.81, 95% CI 0.71–0.93), sarcomatoid histology (OR 0.88, 95% CI 0.80–0.98), Medicaid (OR 0.61, 95% CI 0.5–0.74), Medicare (OR 0.70, 95% CI 0.62–0.79) and no insurance (OR 0.75, 95% CI 0.63–0.91) were associated with significantly decreased systemic therapy use. Male gender (OR 1.05, 95% CI 1.02–1.08) predicted an increased likelihood of systemic therapy.Conclusions:
Systemic therapy in patients undergoing cytoreductive nephrectomy has increased with time, coinciding with the introduction of targeted therapies. Nevertheless, still less than half of such patients receive systemic treatment. While the etiology of the lack of treatment is likely multifactorial, the potential health policy implications of disparities in care warrant further investigation.